BioSpace

Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
BioSpace

Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3

The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...

Merck ADC, licensed from China, hits mark in first big global trial

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
AOL

Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that when ...

Merck Secures EU Backing for Keytruda-Padcev in Bladder Cancer Patients Subset

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.
NDTV

Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works

Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...